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with sorafenib might prove beneficial for metastasized HCC. 
 Randomised studies are needed to confirm this exploratory 
finding.  © 2014 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is the sixth most 
prevalent malignancy and the third most frequent cause 
of cancer-related death worldwide  [1] .
 In recent years, surveillance programs have led to a 
higher rate of detection of HCC in earlier disease stages 
 [1, 2] . However, in most cases HCC is still diagnosed in 
advanced stages. According to the AASLD (American 
Association for the Study of Liver Diseases) and the EASL 
(European Association for the study of the liver) practice 
guidelines, transarterial chemoembolization (TACE) is 
the recommended treatment strategy for patients with 
multinodular disease limited to the liver. For patients 
with extrahepatic spread of HCC, systemic treatment 
with sorafenib is recommended  [1–3] . Some studies have 
assessed the efficacy of a combined treatment with TACE 
and sorafenib in advanced tumour stage compared to 
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 Abstract 
 Background/Aims: For most patients with hepatocellular 
carcinoma (HCC), diagnosis is invariably done only in the ad-
vanced stages of the disease. For advanced, non-metastatic 
stage, standard therapy is transarterial chemoembolization 
(TACE). For metastatic disease, the recommended therapy is 
systemic treatment with sorafenib. In this study, we evalu-
ated the benefit of an additional local hepatic treatment 
for patients with advanced metastatic disease.  Methods: In 
a retrospective study, we assessed the overall survival (OS), 
time to progression (TTP), and disease control rate (DCR) in 
37 patients with metastasized HCC treated with sorafenib. 
Sixteen patients received additional local therapy, while 
21 patients received only sorafenib.  Results: Median OS of 
patients with combined therapy was significantly higher 
with 25 months (95% CI: 13.7–36.3 months) as compared to 
11 months (95% CI: 6.2–15.8 months) in patients treated 
with  sorafenib alone. TTP was 7 months (95% CI: 5.3–8.7 
months) compared to 5 months (95% CI: 3–7 months) and 
DCR was 87 versus 72% after 3 months and 31 versus 22% 
after 9 months.  Conclusion: These data suggest that control 
of the liver tumor burden by local therapy in combination 
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TACE alone  [4–6] . However, these studies recruited pa-
tients usually amenable only to TACE  [4, 5] .
 Prognosis is poor at the metastatic stage. However, in 
most cases, the cause of death is intrahepatic progression 
and liver failure  [7] . Patients in the metastatic stage treat-
ed with sorafenib might therefore benefit from an addi-
tional local hepatic treatment. In this retrospective study, 
we assessed the outcome of patients with metastasized 
HCC treated with sorafenib plus TACE compared to pa-
tients treated only with sorafenib.
 Methods 
 Patients 
 In the time between 2006 and 2012, 37 patients with HCC at 
advanced metastatic stage treated at our hospital according to 
our  institutional and interdisciplinary treatment protocol were 
 enrolled. All patients had HCC diagnosed either histologically 
(19 patients) or by radiologic criteria (18 patients) according to 
 AASLD guidelines  [2] . Their medical charts were retrospectively 
reviewed. We selected 16 patients who were treated with local he-
patic treatment (11 patients treated with TACE, 3 treated with ra-
dioembolization and 2 patients treated with TACE and radioem-
bolization) and sorafenib simultaneously. We matched a control 
group of 21 patients who were treated with sorafenib alone. Pa-
tients were matched by gender (81% male and 19% female patients 
in each group), age (median age was 61 in the combined group and 
65 in the sorafenib group), presence of liver cirrhosis (10 patients 
in the combined vs. 14 patients in the sorafenib group), Child Pugh 
status (7 vs. 10 patients with Child Pugh A, 3 vs. 4 patients with 
Child Pugh B in the combined vs. the sorafenib group only), pri-
mary liver tumour volume (median of 11.5 vs. 12% in the com-
bined vs. the sorafenib group), location of metastasis (8 patients 
had lung metastasis in the combined group and 7 patients in the 
sorafenib only group) and exposed to prior therapies such as resec-
tion, radiofrequency ablation, TACE (50% of patients in the com-
bined and 57% patients in the sorafenib group had a history of 
HCC therapy prior to the current one).
 Treatment 
 TACE and Selective Internal Radiotherapy (SIRT) 
 TACE was performed by the department of interventional ra-
diology by injection of an emulsion of epirubicin and lipiodol into 
tumour-feeding vessels. Patients underwent the procedure every 
8–12 weeks depending on the presence of tumour activity in the 
follow up CT or MRI result (median of numbers of TACE was 
4 (min. 1, max. 10)). SIRT was performed by application of 90-Yt-
trium spheres into the tumour environment. Patients who were 
treated by this therapy received SIRT once or twice.
 Sorafenib 
 Patients treated with sorafenib were prescribed the standard 
dose of two tablets of 200 mg twice daily. Recommended dose re-
duction was done when an adverse event according to CTCAE 3.0 
(Common Terminology Criteria for Adverse Events) occurred. 
Treatment was in general paused 3 days prior and 3 days after 
TACE. Treatment for patients treated with sorafenib alone contin-
ued until radiologic and symptomatic disease progression or intol-
erable adverse events occurred.
 Follow-Up 
 All patients treated at our centre were followed up according to 
our institutional protocol. Follow-up was performed by taking 
medical history, doing physical examination, blood tests and ab-
dominal MRI or CT plus thoracic CT scan every 8–12 weeks. At 
each staging Child Pugh score was assessed as long as data was 
available (for the calculation laboratory values up to 5 days before 
or after the MRI or CT scan were used when data from the same 
day was missing). Depending on these results therapy was contin-
ued, modified or stopped. For this study, evaluation of therapy 
response was done retrospectively by analysing the CT scan or 
MRI according to RECIST (Response Evaluation Criteria In Solid 
Tumors) 1.0 criteria.  [8] Compared to the newer RECIST 1.1 cri-
teria, RECIST 1.0 seemed to be more applicable and precise for this 
study as it allows the measurement of more target lesions  [9] . At 
the end of our evaluation (median follow-up of 8 months), 6 pa-
tients were still in treatment in the combination group and 2 pa-
tients in the sorafenib group.
 Statistical Analysis 
 The primary objective was the overall survival (OS), which was 
defined as the time between the first treatment with TACE and/or 
sorafenib of diagnosed metastatic HCC and death. The time to 
progression (TTP) was defined according to RECIST 1.0  [8] . The 
disease control rate was defined as therapy response including 
complete remission plus partial response plus stable disease. OS 
and TTP were estimated by Kaplan-Meier plots and compared by 
the log-rank test. Baseline patient characteristics were compared 
by using the Students  t test or χ 2 test. Significance was set at p < 
0.05. Statistical analysis was performed using SPSS software ver-
sion 20 (SPSS, Chicago, Ill., USA).
 Results 
 Basic Characteristics of Patients and Disease 
 The basic demographic and disease characteristics at 
the beginning of treatment including age, gender, pres-
ence of cirrhosis, Child Pugh Score, presence of portal vein 
thrombosis, location of metastasis, volume of primary liv-
er lesions, prior treatment are listed in  table 1 . The two 
treatment groups could be properly compared, as there 
was no significant difference in any of the characteristics 
between the two groups. 10 of 16 (62.5%) versus 14 of 21 
(66.7%) patients in the combined versus the sorafenib 
group had liver cirrhosis, 7 versus 10 patients had Child 
Pugh status A and 3 versus 4 patients Child Pugh B (me-
dian for albumin was 4.2 vs. 4.1 g/dl in the combined vs. 
sorafenib group, median for bilirubin was 1.05 vs. 1.10 mg/
dl, INR was 1.10 in each group, 14 vs. 17 patients had no 
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thy). Etiology of liver cirrhosis in both groups was mainly 
chronic alcohol abuse and viral hepatitis; in two patients, 
of the sorafenib group liver cirrhosis was due to hemo-
chromatosis; in seven cases, cirrhosis was cryptogenic. 
Among those patients without liver cirrhosis, three pa-
tients of both groups had steatosis hepatis, one patient in 
the combined treatment group had chronic HBV, and one 
patient of the sorafenib group had histologically diag-
nosed fibrosis for unknown reason. In the other patients 
either no liver disease could be diagnosed or data was lack-
ing. All patients had a good ECOG performance status 
(Eastern Cooperative Oncology group) 0 to 1. Median liv-
er tumour burden was 11.5% in the combination and 12% 
in the sorafenib group. Twelve patients in each group had 
more than 3 liver lesions. Location of metastasis was main-
ly lung (8 of 16 patients in the combination and 7 of 21 
patients in the sorafenib group) and lymph nodes (6 of 16 
and 15 of 21 patients). The majority of patients in both 
groups had singular metastasis (12 and 16 patients). The 
median of the whole size of all metastasis was 2.5 cm (com-
bination group) and 2.0 cm (sorafenib group). Partial por-
tal vein thrombosis was observed in 12.5% of the patients 
(2 patients) in the combined group and in 28.6% of the 
sorafenib patients (6 patients), complete portal vein 
thrombosis was observed in 2 patients of the sorafenib 
only group. Median AFP level was elevated in both groups 
(147 and 221 ng/ml). Prior therapies comprised in both 
groups resection, RFA (radiofrequency ablation) or TACE.
Table 1.  Baseline patient and tumour characteristics at the time of first diagnosis of metastases
Sorafenib + TACE/SIRT Sorafenib p value
Patients, n 16 21
Gender, n (%)
Male 13 (81) 17 (81) 0.982
Female 3 (19) 4 (19)
Age, years, mean ± SD (min–max) 61±9 (46–76) 65±9 (40–79) 0.204
Presence of liver cirrhosis, n (%) 10 (62.5) 14 (66.7) 0.943
Child Pugh score
A 7 10 0.705
B 3 4
Albumin, g/dl (median) 4.2 4.1
Bilirubin, mg/dl (median) 1.1 1.1
INR 1.1 1.1





Etiology of liver cirrhosis, n (%)
HCV 1 (10) 3 (21)
HBV 2 (20) 2 (14)
Chronic alcohol abuse 3 (30) 3 (21)
Alcohol abuse and HCV 1 (10) –
Hemochromatosis – 2 (14)
Cryptogenic 3 (30) 4 (28)
Portal vein thrombosis (partial/complete) 2/0 6/2 0.181
Location of metastases, n (%)
Lung 8 (50) 7 (33) 0.663
Non-lung 8 (50) 14 (67)
Primary liver tumour volume, n (%)
Median 11.5 12 0.723
<10% 8 (50) 9 (43)
10–25% 4 (25) 7 (33)
>25% 4 (25) 5 (24)
Patients with prior therapy, n (%) 8 (50) 12 (57) 0.666




















   
   
   
   
   
   
   
   
   
   
   



























 Overall Survival 
 As shown in  figure 1 a, patients treated with local he-
patic therapy (TACE/SIRT) in addition with sorafenib 
showed a significantly increased median overall survival 
time of 25 months (95% confidence interval: 13.7–36.3 
months) as compared to patients treated with sorafenib 
alone (11 months, 95% CI: 6.2–15.8 months) (p = 0.042). 
After 6 months of follow-up, survival rates were 94% 
(combination group) versus 90% (sorafenib group), and 
75 versus 47% after 12 months of follow-up ( fig. 1 b). At 
the end of our evaluation 6 patients from the combination 
group and 2 patients from the sorafenib group were still 
under treatment.
 To avoid a bias due to the presence of more patients 
with partial and complete portal lacking complete PVT 
and for a cohort lacking both complete and partial PVT, 
we observed for both cohorts a significant better OS in the 
combined treatment group ( fig. 2 ).
 Time to Progression 
 Patients treated with combined therapy seemed to 
progress more slowly median time to progression of 
7  months (95% CI: 5.3–8.7 months) versus 5 months 
(95% CI: 3–7 months); however, this difference was not 
significant (p = 0.531) ( fig. 3 a). Median time to intrahe-
patic progression was 7 months (95% KI: 0–15.23 months) 
versus 8 months (95% KI: 5.96–10.04 months) in the 
combined versus sorafenib only group ( fig. 3 b). Median 
time to extrahepatic progression was 11 months (95% CI: 
2.68–19.32 months) in the combined group versus 
12  months (95% CI: 0–26.53 months) in the sorafenib 
only group ( fig. 3 c). There were neither statistically sig-
nificant differences in the median time to extrahepatic 
(p = 0.701) nor in the time to intrahepatic progression 
(p = 0.938) between the two treatment groups.
 Response Evaluation 
 Patients treated with combined therapy seemed to 
show a higher rate of disease stabilisation and more par-
tial responses (although not statistically significant). Dis-
ease progression seemed to be delayed at 3, 6, and 
9  months compared to the sorafenib group ( fig.  4 a–c). 
After 12  months there was only a slight difference be-
tween the two groups ( fig.  4 d). Disease control rate 
(= complete remission plus partial response plus stable 
disease) after 3, 6, 9, and 12 months was always higher in 
the combined treatment group compared to the sorafenib 
group ( fig. 5 ).
 Fig. 1. Kaplan-Meier analysis of overall survival (left) and survival 
rate (right). For combination group = TACE/SIRT plus sorafenib 
and sorafenib only group. The median overall survival was 25 
months (95% confidence interval: 13.7–36.3 months) in the com-
bination group and 11 months (95% CI: 6.2–15.8 months) in the 
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 Fig. 2. Kaplan-Meier analysis of overall survival for cohorts with-
out complete PVT and without partial or complete portal vein 
thrombosis (PVT). To avoid a bias due to the presence of complete 
PVT in the sorafenib group, data was calculated for a cohort with-
out complete (= total) PVT still showing a significant better OS in 
the combined group (p = 0.031). Data was also calculated for a co-
hort without any PVT also showing a significant better OS for the 














Fig. 3. Kaplan-Meier analysis for time to progression.  a shows time 
to overall progression. The median time to overall progression was 
7 months (95% CI: 5.3–8.7 months) in the combined group and 
5 months (95% CI: 3–7 months) in the sorafenib group and this 
difference was not significant (p = 0.531). Time to intrahepatic 
progression is shown in  b . The median time to intrahepatic pro-
gression was 7 months (95% KI: 0–15.23 months) versus 8 months 
(95% KI: 5.96–10.04 months) in the combined versus the sorafenib-
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 Fig. 4. Therapy response evaluation. Figure 
4 shows the percentage of partial responses, 
stable diseases and progressive diseases af-
ter 3, 6, 9 and 12 months according to 
 RECIST 1.0. There was no case of complete 
remission in both groups. This evaluation 
was only performed for patients with suf-
ficient data at these time points. Few pa-















 Fig. 3. Kaplan-Meier analysis for time to 
progression.  Time to extrahepatic progres-
sion is shown in  c . The median time to ex-
trahepatic progression was 11 months 
(95% CI: 2.68–19.32 months) in the com-
bined group versus 12  months (95% CI: 
0–26.53 months) in the sorafenib-only 
group (p = 0.701). 
p = 0.701
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 Hand-foot-skin reactions due to sorafenib occurred in 
25.8% of the patients in the combined group and only in 
4.8% in the sorafenib only group. Accordingly, dose re-
ductions had to be done more often in the combined 
group (25% of the patients in the combined group vs. in 
9.5% of the patients assigned to sorafenib only). The com-
bined treatment was well tolerated by the small number 
of SIRT patients, 3 of 5 patients had SIRT twice, but dose 
reduction of sorafenib was also necessary in 3 of 5 patients 
of this group.
 The Median Child Pugh score at the beginning of 
treatment was 5 points in each group; even during the 
course of treatment (Child Pugh score was assessed at 
each staging), there was no significant difference (p = 
0.328) between the two groups (online suppl. fig. 1; for all 
online suppl. material, see www.karger.com/doi/10.1159/ 
000367686). Also, changes of INR over time were not sta-
tistically different (p = 0.841). Median bilirubin at the be-
ginning of treatment was similar (1.05 mg/dl in the com-
bined and 1.1 mg/dl in the sorafenib group). However, 
bilirubin increased significantly to higher levels in the 
sorafenib group during treatment (p = 0.049). In the com-
bined group, the median AFP level decreased at the be-
ginning of treatment but increased during the course of 
treatment; conversely, it increased continuously in the 
sorafenib group (p < 0.001) (online suppl. fig. 2).
 Discussion 
 For HCC patients in the advanced metastatic stage 
(BCLC C, Barcelona Clinic Liver Cancer Group), guide-
lines recommend systemic treatment with the multiki-
nase inhibitor sorafenib  [2, 3] . A major activity of 
sorafenib is the inhibition of neoangiogenesis, thereby 
arresting tumour growth by acting on growth factor re-
ceptors like VEGFR and PDGFR, Raf signalling and c-Kit 
 [10, 11] . Its efficacy has been demonstrated in two place-
bo-controlled, randomised phase III trials  [12, 13] . The 
multicenter, double-blind SHARP study, carried out on 
602 patients, showed a median overall survival of 
10.7 months after treatment with sorafenib compared to 
7.9 months in the placebo group  [12] . The Asia Pacific 
study assessed a median overall survival of 6.5 vs. 
4.2 months  [13] . Safety data were reproduced in the large 
phase IV GIDEON study  [14] . 
3 months 6 months 9 months 12 months
87% 43% 31% 15%Combination group






















 Fig. 5. Disease control rate. Disease control 
rate (= complete remission plus partial re-
sponse plus stable disease) after 3, 6, 9 and 




















   
   
   
   
   
   
   
   
   
   
   



























 Transarterial chemoembolisation has become the 
standard treatment for patients in the non-metastatic 
stage not suitable for curative therapy like resection, 
transplantation and image-guided tumour ablation  [1, 
15] .
 Several large studies have reported a survival benefit 
from TACE for patients in an intermediate stage of dis-
ease (BCLC B: multinodular tumour lesions, perfor-
mance status 0, Child Pugh A-B)  [16–19] . Less data is 
available for a survival benefit after treatment with selec-
tive internal radiotherapy (SIRT)  [20–22] .
 A single-centre prospective study of 80 Child Pugh A 
patients in the BCLC stage B with HCV associated HCC 
showed a benefit of sorafenib therapy versus placebo 
 following TACE treatment (TTP of 9.2 vs. 4.9 months) 
 [23] . Similar results were observed in a Japanese and 
 Korean phase III study, where 458 patients in the non-
metastatic stage with Child Pugh A received either 
sorafenib or placebo following TACE treatment. The 
median survival period after a sequential therapy of 
TACE and sorafenib was 29.7 months (however, the me-
dian survival after placebo treatment was not assessed). 
Regarding TTP, there was a slight difference of 5.4 ver-
sus 3.7 months between the sorafenib and the placebo 
group  [24] . It was recently reported in two phase II trials 
that the combination of TACE and sorafenib at the same 
time is well tolerated by patients in the intermediate 
stage (BCLC B) and advanced metastastic stage (BCLC 
C)  [5, 25, 26] . However, overall survival was not as-
sessed. There are recent studies that showed that pa-
tients in the intermediate stage of disease treated with 
TACE might benefit from an additional simultaneous 
systemic therapy  [4, 5, 27, 28] . A reason for the benefit 
of combination therapy might be that sorafenib inverses 
the proangiogenic effect of TACE treatment. The safety 
of combined treatment was shown in a large randomised 
phase II trial (SPACE study)  [29] . This study, which en-
rolled 307 HCC patients in the advanced non-metastat-
ic stage who were randomised in a group treated simul-
taneously with TACE and sorafenib or in a group treat-
ed with TACE and placebo, showed a slight benefit of 
the combined therapy regarding TTP (median TTP in 
the 50th percentile 196 vs. 166 days, 112 vs. 88 in the 
25th percentile and 285 vs. 224 in the 75th percentile in 
the sorafenib vs. placebo group, HR 0.797) but (not yet) 
a significant difference in OS  [29] .
 Cause of death for patients in the metastatic stage is 
rather due to intrahepatic disease progression with con-
secutive liver failure than due to extrahepatic disease pro-
gression  [7] . An additional local hepatic therapy for pa-
tients treated with sorafenib might improve the outcome 
for patients in the metastatic stage. We assessed the ben-
efit of combination therapy of sorafenib with local he-
patic treatment for patients in the advanced metastatic 
stage (BCLC C) in a retrospective study of 37 patients. 
Regarding the baseline patient and tumour characteris-
tics including age, gender, presence of cirrhosis, Child 
Pugh Score, presence of portal vein thrombosis, and liver 
tumour burden, there were no significant differences be-
tween the two treatment groups. We observed a signifi-
cant higher overall survival of 25 months in the combina-
tion group compared to 11 months after sorafenib treat-
ment alone. Survival time for patients under sorafenib 
treatment was similar to the SHARP study result  [12] . 
The retrospective study by Qu et al., carried out on 45 pa-
tients of HCC in the intermediate and advanced stages, 
observed a similar overall survival of 27 months after 
combined TACE and sorafenib treatment compared to 
17 months after TACE treatment alone  [4] .
 Patients with complete portal vein thrombosis are usu-
ally not treated by TACE and are supposed to have a 
worse prognosis. In order to prove that the worse prog-
nosis of the sorafenib only group is not due to the pres-
ence of more patients with partial and complete portal 
vein thrombosis in this group we calculated the data for a 
cohort lacking complete portal vein thrombosis and for a 
cohort lacking any type of portal vein thrombosis. We as-
sessed a significant better OS in the combined group 
demonstrating that this is not due to the presence of com-
plete PVT in the sorafenib group.
 We observed a higher disease control rate in the com-
bination group after 12 months of follow-up. In our study, 
the disease seemed to progress more slowly after com-
bined treatment compared to sorafenib treatment alone 
7 months (95% CI: 5.3–8.7) versus 5 months (95% CI: 
3–7). However, this difference regarding the TTP was not 
statistically significant between the two therapy arms. Ac-
cordingly, there was a significant difference neither in the 
intrahepatic nor in the extrahepatic progress. TTP mea-
sures the time until the first progression and the effect of 
combined treatment might be seen later during time 
course. Accordingly, although there was no significant 
difference in the time course of liver function, AFP levels 
increased significantly faster in the sorafenib-only group. 
This might indicate a faster progress in the sorafenib 
group over the course of treatment independently of the 
liver function. This is supported by the higher disease 
control rate in the combined group.
 The main limiting factors of our study are the small 
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may have caused the missing of some data and a bias in 
some cases. The main baseline characteristics at the be-
ginning of treatment however were not statistically sig-
nificant between the two groups. During the time course 
of treatment, some laboratory results could not be as-
sessed for all patients. The decision for a combined or 
sorafenib only treatment was made individually based 
on clinical criteria. About 56.2% of patients in the com-
bination group versus 38.1% in the sorafenib group 
showed a metastatic stage when first diagnosed for HCC. 
Patients who were first diagnosed at the metastatic stage 
might have been offered a combined treatment rather 
than sorafenib treatment alone. Patients who showed 
disease progression after prior therapies might have 
rather received sorafenib alone rather than the combi-
nation. However, the number of patients with prior 
therapies was not significantly different in both groups 
(8 vs. 12 patients in the combined vs. the sorafenib 
group). Although more dose reductions had to be done 
in the combination group (due to hand-foot-skin reac-
tion) than in the sorafenib group (25 vs. 9.5%), patients 
showed a higher rate of therapy response in the com-
bined group.
 Conclusion 
 Recent studies showed that HCC patients in the inter-
mediate stage of disease treated with TACE might benefit 
of an additional systemic therapy. A reason for that might 
be that sorafenib inverses the proangiogenic effect of 
TACE treatment. Cause of death for patients in the meta-
static stage is intrahepatic rather than extrahepatic pro-
gression of disease. Our study suggests that patients in the 
metastastic stage of disease might benefit from local treat-
ment of the primary liver lesions in addition to systemic 
therapy because we observed a significantly higher OS af-
ter combined treatment. However, studies with higher 
numbers of patients in a prospective trial are needed be-
fore general recommendations for a combination therapy 
could be given to patients in the metastatic stage.
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